Six‐Month Real‐World Effectiveness, Persistence and Safety of Low‐to‐Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study
Authors' conclusion
In routine clinical practice, low-to-moderate dose tirzepatide was associated with clinically meaningful weight loss at 6 months, high treatment persistence, and acceptable tolerability.
Study context
- Population
- Adults with obesity initiating tirzepatide in routine practice, 15 endocrinology clinics in Greece, December 2024–May 2025208 completed 6 months
- Participants
- 260 adults
- Outcome
- Weight-loss outcomes, treatment persistence and safety
- Follow-up
- 6 months
Methodological detailsmulticentre, real-world
- Multicentre
- Real-world
Main finding
As reported in the abstract
Weight loss
- Achieved ≥ 5% weight loss
- 94.2%
- Achieved ≥ 10% weight loss
- 77.9%
- Achieved ≥ 15% weight loss
- 47.1%
- Achieved ≥ 20% weight loss
- ≈20%
- Body weight and body mass index (BMI) decreased significantly from baseline, with a large effect size
- p < 0.001
Observational data: associations, not effects.
Further findings
Weight loss by baseline BMI, obesity class and sex · 6 months
- Women achieved greater percentage weight loss than men
- P = 0.042
- Weight-loss magnitude independent of baseline BMI and obesity class
Treatment persistence · 6 months
- Treatment discontinuation, mostly during titration, primarily due to goal achievement, cost, non-response or adverse events
- 20%
Safety
- Gastrointestinal adverse events most frequent but rarely led to discontinuation
Original publication
Six‐Month Real‐World Effectiveness, Persistence and Safety of Low‐to‐Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study. Diabetes Obes Metab. Published 27 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →